Conclusion
Permanent visual toxicity can be an adverse event shared between TKIs, possibly through a common mechanism of action, being a limiting factor for the use of these drugs in some cases (mainly in older patients with known ocular deficits). Treatment with corticosteroids did no improvement in this clinical case, as well as the change of TKI therapy. The decision to reduce dose or discontinue a TKI should be made after a risk–benefit analysis.